Chronic Pain News and Research RSS Feed - Chronic Pain News and Research

First commercial procedure performed using Senza system for delivering Nevro's HF10 therapy

Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy. [More]

DyAnsys' new non-narcotic treatment solution may provide relief to chronic pain sufferers

Chronic pain sufferers may find relief with a new, safe and effective non-narcotic treatment solution released by medical device maker DyAnsys, Inc. The company announced today that the four-piece system will be available in select doctors' offices and pain management centers. [More]
Fibromyalgia now considered as a lifelong central nervous system disorder

Fibromyalgia now considered as a lifelong central nervous system disorder

Fibromyalgia is the second most common rheumatic disorder behind osteoarthritis and, though still widely misunderstood, is now considered to be a lifelong central nervous system disorder, which is responsible for amplified pain that shoots through the body in those who suffer from it. [More]
APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

The American Pain Society today honored the recipients of its annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers. Five multidisciplinary pain programs were recognized. [More]
APS announces recipients of prestigious achievement awards during annual scientific meeting

APS announces recipients of prestigious achievement awards during annual scientific meeting

The American Pain Society (APS), www.americanpainsociety.org, today announced the recipients of its prestigious achievement awards during the organization's annual scientific meeting. [More]
Nevro Q1 revenue increases 45% to $9.7 million

Nevro Q1 revenue increases 45% to $9.7 million

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015. [More]
Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system. [More]
Specific brain chemical may play role in promoting chronic pain

Specific brain chemical may play role in promoting chronic pain

A chemical in the brain typically associated with cognition, movement and reward-motivation behavior -- among others -- may also play a role in promoting chronic pain, according to new research at The University of Texas at Dallas. [More]
Researchers report new primary care model to address trauma

Researchers report new primary care model to address trauma

Recognizing that patients' experiences of childhood and adult trauma are common and have a direct impact on their health, UCSF clinical researchers and Positive Women's Network-USA have developed and are reporting a new primary care model. [More]
New study finds link between childhood maltreatment and adult sleep problems

New study finds link between childhood maltreatment and adult sleep problems

Adults who experienced multiple incidents of childhood maltreatment were more than two times as likely to have trouble sleeping than their counterparts who were not maltreated during childhood, according to a new study from researchers at the University of Toronto, University of Ottawa, and Western University. [More]
Only few sexually assaulted servicewomen seek post-assault health care, study finds

Only few sexually assaulted servicewomen seek post-assault health care, study finds

Despite growing public awareness of sexual assault of women during their military service and increased efforts by the Department of Defense to deter sexual crimes and encourage reporting and help-seeking, a Veterans Affairs study suggests most female service members who experience sexual assault are still unlikely to seek post-assault health care, at least in the short term. [More]
Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's. [More]
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. [More]
Scientists use special MRI imaging to predict chronic pain, disability and PTSD after whiplash injury

Scientists use special MRI imaging to predict chronic pain, disability and PTSD after whiplash injury

While most people should expect to fully recover from whiplash injuries within the first few months, about 25 percent have long-term pain and disability that lasts many months or years. [More]
Study provides new estimates of opioid misuse, addiction

Study provides new estimates of opioid misuse, addiction

New estimates suggest that 20 to 30 percent of opioid analgesic drugs prescribed for chronic pain are misused, while the rate of opioid addiction is approximately 10 percent, reports a study in the April issue of PAIN, the official journal of the International Association for the Study of Pain. [More]
Higher levels of vitamin D decrease pain, improve function in obese patients with osteoarthritis

Higher levels of vitamin D decrease pain, improve function in obese patients with osteoarthritis

Got milk? If you are overweight and have osteoarthritis, you may want to bone up on your dairy products that have vitamin D. [More]
Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed. [More]
Top experts focus on musculoskeletal disorders in open key Congress in Milan

Top experts focus on musculoskeletal disorders in open key Congress in Milan

Musculoskeletal conditions, which affect over 1.7 billion people worldwide, will be the focus of a major four-day Congress which opens today in Milan, Italy. [More]
VIVA physician selected as new Fellows in the Society of Interventional Radiology

VIVA physician selected as new Fellows in the Society of Interventional Radiology

Dr. John D. Statler, a board-certified, fellowship-trained Interventional Radiologist with Virginia Interventional & Vascular Associates, is one of only 23 physicians nationwide selected this year as new Fellows in the Society of Interventional Radiology. [More]
Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine. [More]
Advertisement